About Cryotherapeutics

Creathor Venture, one of the leading European Venture Capital firms, leads a Series B financing round in CryoTherapeutics, the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease. The Life Science Start-up CryoTherapeutics receives at total of € 5.2 million in the current Series B financing round from Creathor Venture as well as from the existing investors NRW.BANK, Peppermint CBF, High-Tech Gründerfonds (HTGF), Getz Brothers, Kreditanstalt für W

CryoTherapeutics GmbH (CryoTherapeutics), the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease, announced today that it has completed an extension to its Series A financing round led by Peppermint Venture Partners (PVP) via its Charité Biomedical Fund with participation by existing investors NRW.BANK, Rainer Christine Asset Management GmbH, High-Tech Gründerfonds (HTGF) and Getz Brothers. New investor KfW also participated in the financing. C

CryoTherapeutics GmbH (CryoTherapeutics), the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease, announced today that it has completed a second closing of its Series A financing round, with Peppermint VenturePartners (PVP) via its new Charité Biomedical Fund joining the investor consortium. The additional investment by PVP is in addition to the Series A financing round closed in June 2012 by NRW.BANK, High-Tech Gründerfonds (HTGF), private invest